The GLP-1 [glucagon-like peptide 1] agents are poised to become viable options for treating indications beyond type 2 ...

The 1.0 era of isolated telehealth is finally dead. We’re thrilled to welcome the new era of connected telehealth. In this ...

Health plans in 2025 will pay more attention to cybersecurity. While the majority of hacks and breaches target healthcare ...

In an investor call, Andrew Witty promised full transparency and 100% pass-through rebates for prescription drugs by 2028.

The investigational drug, called PMD-026, is currently in phase 2 clinical trials for the treatment of breast cancer.

In 2024, UnitedHealth Group saw full year revenue grow 8% over 2023 to reach $400.3 billion. Adjusted earnings from ...

Most infants born before December were administered nirsevimab, while those whose mothers reached eligible gestational age ...

The healthcare industry can’t afford to be stagnant. Cost pressures, operational pressures and real human lives are at stake ...

A South Korean study explored the link between lifestyle decisions beginning in infancy and persistent atopic dermatitis, ...

In 2025, AI [artificial intelligence] will play a larger role in driving payer operational improvements and offer health insurers a more comprehensive view of member health.

The Federal Trade Commission suggests that PBMs profit from specialty generic drugs such as those for cancer and HIV and ...

Sana Biotechnology’s hypoimmune platform enables it to make a series of genetic modifications to cells, rendering the cells ...